Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

Table 3

Details of immune-related adverse events leading to discontinuation of anti-PD-1 therapy and their treatment.

Patient Number	irAE leading to discontinuation of anti-PD-1 therapy	Time of first presentation of any grade irAE from initiation of therapy (months)	Immune suppressive agents for treatment of irAE
1	Grade 2 inflammatory arthritis and neuropathy	4.1	Prednisone
2	Grade 2 diarrhea	4	Budesonide
3	Grade 3 colitis and diarrhea	2.6	Prednisone, budesonide
	Grade 2 adrenal insufficiency	4.1	Hydrocortisone
4	Grade 3 sensorimotor polyneuropathy	2.3	Prednisone
5	Grade 1 diarrhea	2.8	Budesonide
	Grade 3 pancreatitis and colitis	3.5	Budesonide
6	Grade 3 rash	11.5	Dexamethasone, topical steroids
7	Grade 2 inflammatory arthritis	4.6	Prednisone, methotrexate
8	Grade 2 fatigue, nausea, diarrhea, arthritis	4.8	None
9	Grade 3 pancreatitis	6.5	Prednisone
10	Grade 2 nephritis	6.9	Prednisone
11	Grade 2 hypothyroidism, low mood, mouth sores, rash	9.7	Topical steroids
12	Grade 3 rash	0.5	Prednisone
13	Grade 3 hepatitis	2.1	Prednisone, budesonide
14	Grade 3 uveitis	3.9	Prednisone, ophthalmic prednisolone
15	Grade 3 rash	11.3	Prednisone, topical steroids
16	Grade 4 myasthenia flare	0.8	Plasma exchange, mycophenolate mofetil, prednisone, intravenous immunoglobulin, abatacept

IrAE: immune-related adverse events.